Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Suresh Venkateswaran is active.

Publication


Featured researches published by Suresh Venkateswaran.


Pediatric Clinics of North America | 2017

Nonclassic Inflammatory Bowel Disease in Young Infants: Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome, and Other Disorders

Shanmuganathan Chandrakasan; Suresh Venkateswaran; Subra Kugathasan

This article discusses non-classical forms of inflammatory bowel disease (IBD) mainly occurs in infants and very young children. Defects in every aspect of the immune system, such as neutrophils, T-cell and B-cell lymphocytes, and macrophages are associated with IBD in infants. Also, non lympho-hematopoietic defects with primary defects in enterocytes can also lead to IBD-like manifestations. Clinical vignettes are presented and the genetic origins and possible management strategies are outlined. Early evaluation of these patients is important because identification of underlying immune defects would facilitate the use of better-targeted therapy for the specific genetic defect.


The American Journal of Gastroenterology | 2018

The Effect of Early-Life Environmental Exposures on Disease Phenotype and Clinical Course of Crohn’s Disease in Children

Livia Lindoso; Kajari Mondal; Suresh Venkateswaran; Hari Somineni; Cortney R. Ballengee; Thomas D. Walters; Anne M. Griffiths; Joshua D. Noe; Wallace Crandall; Scott B. Snapper; Shervin Rabizadeh; Joel R. Rosh; Neal Leleiko; Stephen L. Guthery; David R. Mack; Richard Kellermayer; Ajay S. Gulati; Marian D. Pfefferkorn; Dedrick E. Moulton; Stanley N. Cohen; Maria Oliva-Hemker; Melvin B. Heyman; Anthony Otley; Susan S. Baker; Jonathan Evans; Barbara S. Kirschner; Ashish S. Patel; David Ziring; Michael Stephens; Robert N. Baldassano

OBJECTIVES: Environmental factors play an important role in the pathogenesis of Crohns Disease (CD). In particular, by virtue of the instability of the microbiome and development of immunologic tolerance, early life factors may exert the strongest influence on disease risk and phenotype. METHODS: We used data from 1119 CD subjects recruited from RISK inception cohort to examine the impact of early life environment on disease progression. Our primary exposures of interest were breastfeeding in infancy and exposure to maternal, active, or passive smoke. Our primary outcomes were development of complicated (stricturing or penetrating) disease, and need for CD‐related hospitalization, and surgery. Multivariable logistic regression models were used to define independent associations, adjusting for relevant covariates. RESULTS: Our study cohort included 1119 patients with CD among whom 15% had stricturing (B2) or penetrating disease (B3) by 3 years. 331 patients (35%) and 95 patients (10.6%) required CD‐related hospitalizations and surgery respectively. 74.5% were breastfed in infancy and 31% were exposed to smoking among whom 7% were exposed to maternal smoke. On multivariable analysis, a history of breastfeeding was inversely associated with complicated (B2/B3 disease) 0.65, CI 95% 0.44‐96; P = 0.03) in pediatric CD. Maternal smoking during pregnancy was associated with increased risk of hospitalization during the 3‐year follow‐up period (OR 1.75, CI 95% 1.05‐2.89; P = 0.03). CONCLUSIONS: Early life environmental factors influence the eventual phenotypes and disease course in CD.


Inflammatory Bowel Diseases | 2018

Free and Bioavailable 25-Hydroxyvitamin D Concentrations are Associated With Disease Activity in Pediatric Patients With Newly Diagnosed Treatment Naïve Ulcerative Colitis

Cary G. Sauer; Matthew Shane Loop; Suresh Venkateswaran; Vin Tangpricha; Thomas R. Ziegler; Ashish Dhawan; Courtney McCall; Erin Bonkowski; David R Mack; Brendan Boyle; Anne M. Griffiths; Neal Leleiko; James Markowitz; Susan S. Baker; Joel R. Rosh; Robert N. Baldassano; Sonia M. Davis; Shiven Patel; Jessie Wang; Alison Marquis; Krista Spada; Subra Kugathasan; Thomas D. Walters; Jeffrey S. Hyams; Lee A. Denson

Background Vitamin D regulates intestinal epithelial and immune functions, and vitamin D receptor deficiency increases the severity of murine colitis. Bioavailable 25-hydroxyvitamin D (25(OH)D) is available to target tissues and may be a driver of immune function. The aim is to evaluate the relationship of bioavailable 25(OH)D to the clinical expression of treatment naive pediatric ulcerative colitis (UC). Methods The PROTECT (Predicting Response to Standardized Pediatric Colitis Therapy) study enrolled children ≤17 years newly diagnosed with UC. Free and total 25(OH)D were directly measured and 25(OH)D fractions were compared with disease activity measures. Results Data were available on 388 subjects, mean age 12.7 years, 49% female, 84% with extensive/pancolitis. The median (IQR) total 25(OH)D concentration was 28.5 (23.9, 34.8) ng/mL, and 57% of subjects demonstrated insufficient vitamin D status (25(OH)D < 30 ng/mL). We found no evidence of association between total 25(OH)D and disease activity. Regression models adjusted for age, sex, race, and ethnicity demonstrated that an increase from 25th to 75th percentile for bioavailable and free 25(OH)D were associated with a mean (95th CI) decrease in the Pediatric Ulcerative Colitis Activity Index (PUCAI) of -8.7 (-13.7, -3.6) and -3.1 (-5.0, -1.2), respectively. No associations were detected between 25(OH)D fractions and fecal calprotectin or Mayo endoscopy score. Conclusions Vitamin D insufficiency is highly prevalent in children with newly diagnosed UC. We found associations of free and bioavailable, but not total 25(OH)D, with PUCAI. Bioavailable vitamin D may contribute to UC pathophysiology and clinical activity.


Inflammatory Bowel Diseases | 2018

Enhanced Contribution of HLA in Pediatric Onset Ulcerative Colitis

Suresh Venkateswaran; Jarod Prince; David J. Cutler; Urko M. Marigorta; David T. Okou; Sampath Prahalad; David R. Mack; Brendan Boyle; Thomas D. Walters; Anne M. Griffiths; Cary G. Sauer; Neal Leleiko; James Markowitz; Susan S. Baker; Joel R. Rosh; Marian D. Pfefferkorn; Melvin B. Heyman; Ashish S. Patel; Anthony Otley; Robert N. Baldassano; Joshua D. Noe; Paul A. Rufo; Maria Oliva-Hemker; Sonia M. Davis; Michael E. Zwick; Greg Gibson; Lee A. Denson; Jeffrey S. Hyams; Subra Kugathasan

Background The genetic contributions to pediatric onset ulcerative colitis (UC), characterized by severe disease and extensive colonic involvement, are largely unknown. In adult onset UC, Genome Wide Association Study (GWAS) has identified numerous loci, most of which have a modest susceptibility risk (OR 0.84-1.14), with the exception of the human leukocyte antigen (HLA) region on Chromosome 6 (OR 3.59). Method To study the genetic contribution to exclusive pediatric onset UC, a GWAS was performed on 466 cases with 2099 healthy controls using UK Biobank array. SNP2HLA was used to impute classical HLA alleles and their corresponding amino acids, and the results are compared with adult onset UC. Results HLA explained the almost entire association signal, dominated with 191 single nucleotide polymorphisms (SNPs) (p = 5 x 10-8 to 5 x 10-10). Although very small effects, established SNPs in adult onset UC loci had similar direction and magnitude in pediatric onset UC. SNP2HLA imputation identified HLA-DRB1*0103 (odds ratio [OR] = 6.941, p = 1.92*10-13) as the most significant association for pediatric UC compared with adult onset UC (OR = 3.59). Further conditioning showed independent effects for HLA-DRB1*1301 (OR = 2.25, p = 7.92*10-9) and another SNP rs17188113 (OR = 0.48, p = 7.56*10-9). Two HLA-DRB1 causal alleles are shared with adult onset UC, while at least 2 signals are unique to pediatric UC. Subsequent stratified analyses indicated that HLA-DRB1*0103 has stronger association for extensive disease (E4: OR = 8.28, p = 4.66x10-10) and female gender (OR = 8.85, p = 4.82x10-13). Conclusion In pediatric onset UC, the HLA explains almost the entire genetic associations. In addition, the HLA association is approximately twice as strong in pediatric UC compared with adults, due to a combination of novel and shared effects. We speculate the paramount importance of antigenic stimulation either by infectious or noninfectious stimuli as a causal event in pediatric UC onset.


Inflammatory Bowel Diseases | 2018

Evolution of Pediatric Inflammatory Bowel Disease Unclassified (IBD-U): Incorporated With Serological and Gene Expression Profiles

Raguraj Chandradevan; Tatyana Hofmekler; Kajari Mondal; Nusrat Harun; Suresh Venkateswaran; Hari Somineni; Cortney R. Ballengee; Mi-Ok Kim; Anne M. Griffiths; Joshua D. Noe; Wallace Crandall; Scott B. Snapper; Shervin Rabizadeh; Joel R. Rosh; Thomas D. Walters; Madeline Bertha; Marla C. Dubinsky; Lee A. Denson; Cary G. Sauer; James Markowitz; Neal S. Leleiko; Jeffrey S. Hyams; Subra Kugathasan

Background Inflammatory bowel disease (IBD) mainly consists of Crohns disease (CD) and ulcerative colitis (UC). About 10%-15% of patients with IBD cannot be firmly diagnosed with CD or UC; hence, they are initially diagnosed as inflammatory bowel disease unclassified (IBD-U). Having a firm diagnosis is clearly preferred to guide treatment choices, and better understanding of the nature of IBD-U is required. Methods We performed an analysis of a subset of pediatric subjects from an inception IBD cohort of patients initially enrolled in a prospective multicenter study (the RISK study). Initial diagnosis and 2-year follow-up data from the subjects diagnosed with IBD-U were analyzed. An expert panel verified final diagnosis using predefined criteria as a guide. Serological and disease-relevant ileal and rectal tissue gene expression profiles were investigated. The use and the time to initiate anti-TNFα treatment was analyzed among the outcome groups. Results A total of 1411 subjects were enrolled with initial diagnosis of IBD, and among them, 136 subjects were initially diagnosed as IBD-U at enrollment. And 26% were reclassified as UC and 14% as CD within 2 years of diagnosis, while 60% remained as IBD-U. Of those who were reclassified, there was a 2:1 ratio, UC (n = 35) to CD (n = 19). The molecular and serological features of IBD-U at the end of follow-up were very similar to UC and very different from CD. There was less likelihood of receiving anti-TNFα agents if the diagnosis was IBD-U compared with CD (P < 0.0001). Conclusions In our cohort, 60% of the IBD-U subjects remained as unclassified at 2 years; of those subsequently classified, a higher percentage followed a course more similar to UC. Most of the IBD-U subjects at diagnosis had serological and molecular signatures that are very similar to UC. Although the atypical presentations made the clinician to make an interim diagnosis of IBD-U, results of the molecular and serological factors performed at the time of diagnosis suggests that they were very similar to UC. However, long-term studies are needed to better understand the natural history and molecular characterization of pediatric onset IBD-U. 10.1093/ibd/izy136_video1Video 1.Video 1. Watch now at https://academic.oup.com/ibd/article-lookup/doi/10.1093/ibd/izy136izy136.video15791389938001.


Cellular and molecular gastroenterology and hepatology | 2018

Bowel Location Rather Than Disease Subtype Dominates Transcriptomic Heterogeneity in Pediatric IBD

Suresh Venkateswaran; Urko M. Marigorta; Lee A. Denson; Jeffrey S. Hyams; Greg Gibson; Subra Kugathasan

Genome-wide association studies have uncovered approximately 250 common loci with strong associations in inflammatory bowel disease (IBD). The current challenge is to understand the underlying molecular mechanisms whereby each locus predisposes to IBD. In this regard, transcriptomic profiling dissecting gene expression patterns in tissues where the chronic inflammation occurs, as well as studies on its genetic control (expression quantitative trail loci [eQTL]), are beginning to shed some light into IBD pathophysiology. However, data sets profiling patients to explore changes in gene expression across gastrointestinal locations relevant to the disease (eg, ileum vs colon) are lacking and no eQTL studies available are based on transcriptomic profiling of pediatric IBD. We used genetic and transcriptomic data from the Risk Stratification and Identification of Immunogenetic and


Gastroenterology | 2017

Genome-Wide Association Study Identifies African-Specific Susceptibility Loci in African Americans With Inflammatory Bowel Disease

Steven R. Brant; David T. Okou; Claire L. Simpson; David J. Cutler; Talin Haritunians; Jonathan P. Bradfield; Pankaj Chopra; Jarod Prince; Ferdouse Begum; Archana Kumar; Chengrui Huang; Suresh Venkateswaran; Lisa W. Datta; Zhi Wei; Kelly Thomas; Lisa J. Herrinton; Jan Micheal A. Klapproth; Antonio Quiros; Jenifer Seminerio; Zhenqiu Liu; Jonathan S. Alexander; Robert N. Baldassano; Sharon Dudley-Brown; Raymond K. Cross; Themistocles Dassopoulos; Lee A. Denson; Tanvi Dhere; Gerald W. Dryden; John S. Hanson; Jason K. Hou


Gastroenterology | 2018

P150 MICROBIOME RISK SCORE (MRS) IN THE DIAGNOSIS AND CLASSIFICATION OF INFLAMMATORY BOWEL DISEASE

Khuong Le; Hari Somineni; Suresh Venkateswaran; Pankaj Chopra; Arjuna Karikaran; Anne Dodd; Jarod Prince; Jordan Weitzner; Subra Kugathasan


Inflammatory Bowel Diseases | 2018

10 EPIGENOME-WIDE ASSOCIATION STUDY IDENTIFIED SHARED METHYLOMIC CONTRIBUTIONS TO SUSCEPTIBILITY AND PROGRESSION IN PEDIATRIC CROHN’S DISEASE

Hari Somineni; Suresh Venkateswaran; Varun Kilaru; Pankaj Chopra; David T. Okou; Jeffrey S. Hyams; Lee A. Denson; David J. Cutler; Greg Gibson; Karen N. Conneely; Alicia K. Smith; Subra Kugathasan


Gastroenterology | 2018

10 EPIGENOME-WIDE ASSOCIATION STUDY IDENTIFIED SHARED METHYLOMIC CONTRIBUTIONS TO SUSCEPTIBILITY AND PROGRESSION IN PEDIATRIC CROHN'S DISEASE

Hari Somineni; Suresh Venkateswaran; Varun Kilaru; Pankaj Chopra; David T. Okou; Jeffrey S. Hyams; Lee A. Denson; David J. Cutler; Greg Gibson; Karen N. Conneely; Alicia K. Smith; Subra Kugathasan

Collaboration


Dive into the Suresh Venkateswaran's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lee A. Denson

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Joel R. Rosh

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Robert N. Baldassano

Children's Hospital of Philadelphia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

James Markowitz

North Shore-LIJ Health System

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge